IMF Videos Search Content For Healthcare Professional (122) Healthcare Provider (122) Care Partner (75) Patient (74) Series - Any - ASCO/EHA (49) ASH (60) Ask Dr. Durie (16) Black Swan Research Initiative (5) Community Workshops (4) Emerging Therapies (6) Facebook Live (10) Health Equity (2) IMWG (3) Inspirational (3) Living Well with Myeloma (4) Myeloma in a Minute (1) Myeloma Made Simple (3) Patient & Family Webinar (4) Q&A (7) Recent News and Developments (4) Treatments (1) Trending Searches in Myeloma (1) Topics Clinical Trials (184) Financial Considerations (15) Frontline Therapy (81) Health Equity (33) Inspirational Stories (23) Insurance (6) Lab & Imaging Tests (68) Lifestyle (47) Mental & Emotional Health (28) Myeloma 101 (54) Myeloma in the News (7) Public Policy & Advocacy (17) Q&A's (41) Recorded Seminars & Workshops (14) Recorded Webinars (23) Relapse/Refractory Myeloma (135) Research Updates (192) Symptom Management (113) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (65) High-Risk Myeloma (42) High-risk Smoldering Myeloma (34) Late Relapse (4–6 Lines of Therapy) (81) MGUS (35) Newly Diagnosed (Pre-Treatment or First Treatment) (64) Smoldering Myeloma (50) Types of Therapy Immunomodulatory drugs (IMiDs) (58) Immunotherapies (CAR T; BiTE, etc.) (93) Monoclonal antibodies (48) Proteasome inhibitors (43) Stem cell transplant (40) Steroids (41) Supportive Care (36) Year Published 2026 (16) 2025 (38) 2024 (58) 2023 (39) 2022 (10) 2021 (7) 2020 (1) 2019 (9) 2018 (2) 2017 (1) 2016 (3) Trusted Voices Dr. Joseph Mikhael (36) Dr. Brian GM Durie (15) Dr. María-Victoria Mateos (6) Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO (5) Dr. Saad Usmani (3) Dr. Sigurður Kristinsson (3) Dr. Shaji Kumar (2) Dr. Urvi A. Shah (2) Dr. Sagar Lonial (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance MajesTEC-1: Longer Follow-up Teclistamab + Tocilizumab Prophylaxis for CRS in Relapsed/Refractory Myeloma June 21, 2024 ASCO/EHA Efficacy, Safety, and Determination of ABBV-383, a BCMA Bispecific Antibody, in Patients with Relapsed Refractory Multiple Myeloma June 21, 2024 ASCO/EHA LINKER-MM1: Linvoseltamab for RR Multiple Myeloma Deep, Durable Responses at 14-Month Follow-Up June 20, 2024 ASCO/EHA What does the FDA approval of MRD testing for myeloma mean for patients and drug development? June 20, 2024 Ask Dr. Durie Idecabtagene Vicleucel for High-Risk Early Relapse Multiple Myeloma - KarMMa-2 Study June 19, 2024 ASCO/EHA IMROZ: Isa-VRd vs VRd for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma June 17, 2024 ASCO/EHA DREAMM-8 Study: Belantamab mafodotin plus pomalidomide and dexamethasone shows improved outcomes in relapsed/refractory multiple myeloma June 14, 2024 ASCO/EHA Isatuximab Plus Len/Dex/Bortezomib vs IsaRd in Newly Diagnosed Transplant Ineligible Multiple Myeloma June 12, 2024 ASCO/EHA Improved Depth of Response and MRD Negativity with DARA + VRd in Transplant-Eligible NDMM: PERSEUS Trial Results June 10, 2024 ASCO/EHA Cevostamab Shows Promise in Hard-to-Treat Multiple Myeloma June 6, 2024 ASCO/EHA Myeloma Made Simple: Bispecific Antibody Targets Made Simple | Myeloma Targeting with Bispecifics June 6, 2024 Myeloma Made Simple Myeloma Made Simple: Xpovio (Selinexor) Made Simple | Selinexor for Multiple Myeloma Treatment May 15, 2024 Myeloma Made Simple Load More
